Home » FDA Warns Compounding Pharmacy Trio With cGMP Violations
FDA Warns Compounding Pharmacy Trio With cGMP Violations
The FDA cited a trio of compounders for a wide swath of quality violations, igniting renewed criticism that the agency is “unjustified” in using a new law to enforce old violations.
Drug Industry Daily
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May